ARCHIVES

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Concerned About Data-Dredging In Drug-Diagnostic Applications

January 30, 2009

Treanda Approved For B-Cell Non-Hodgkin’s Lymphoma

October 31, 2008

Obey Says NCI “Must Do Better,” Response Dispute GAO Conclusion

August 8, 1980

NCAB Committee Approves Staff Plan For New Comprehensive Cancer Center Grant Mechanism

April 29, 1988

New P01 Guidelines Will Go Into Effect Feb. 1 Not Oct. 1

September 16, 1983

In Brief: Gramm-Rudman-Hollings Could Slash NCI Budget By $650 Million; Holleb Retires From ‘Ca’

July 27, 1990